DEA 7-OH Update: October 2026 Scheduling Explained
The October announcements raised plenty of questions. Here’s how to read them without confusing a proposal with an order already in force.
What changed?
On October 9, 2026, DOJ announced updated DEA scheduling plans for 7-OH and related substances. HHS recommended using both concentration and ratio thresholds to distinguish trace amounts from enhanced products. New notices appeared in the Federal Register on October 14. Those documents matter more than a headline or a screenshot.
What do the thresholds describe?
The recommendation covers 7-OH and MGPI, separately or combined: more than 1 mg per gram in solid products or 1 mg per milliliter in liquids, or a mitragynine-to-these-substances ratio below 100:1. These are scheduling criteria. They aren’t serving instructions or a measure of safety.
A notice is a step, not the finish line
The October 9 DOJ announcement said a temporary scheduling order for 7-OH had not yet been issued. It also said the August 26 controls on MGPI, MGM-15, and MGM-16 would remain during the new notice period. Read the October 14 notices for the next procedural steps; don’t assume a new proposal has already replaced an existing order.
What should you check next?
Start with the actual substance named, the publication date, and whether the document is a notice or an effective order. This update was checked October 15, 2026. It doesn’t settle state or local rules, approve a product, or establish that a seller’s stock is lawful. Use the official documents for a current legal question.
Sources & further reading
For adults 21+. These guides offer general information, not personal medical or legal advice. For a question about your health, medicines, or legal situation, speak with a qualified professional.